Racial and Socioeconomic Disparities in Colorectal Cancer Screening During the COVID-19 Pandemic

INTRODUCTION: Colorectal cancer (CRC) screening has reduced CRC mortality. The COVID-19 pandemic led to a reduction in screening volume. We sought to evaluate whether specific populations or socioeconomic groups were disproportionately impacted by the reduced access to care. METHOD(S): Patients eligible for CRC screening in a large integrated healthcare system, who had a primary care visit between January 2016 and April 2022, were evaluated. Trends in CRC screening were assessed by age, race, gender, insurance type, and geographic delineation by state and classification of urban or rural areas. Multilevel logistic regression models evaluated region-level cluster effects of CRC screening by patient demographics, insurance, and social vulnerability index (SVI), including socioeconomic status, household composition and disability, minority status and language, and housing and transportation domains. The interaction between trend in CRC screening and race was also investigated. RESULT(S): A total of 654,386 patients were screeneligible between January 2016 and April 2022. The cohort screening rate peaked at 70% in 2019 with a subsequent downtrend to a nadir of 63.6% through the first part of 2022. Whereas the Native American population is consistently the least screened population, the Asian population demonstrated the most significant decrease in screening during and after the COVID-19 pandemic, falling from a peak at 69.1% in 2019 to 59.3% in 2021;this remains low in 2022 at 58.9%. Further, older patients, males, location in an urban area, White ethnicity and use of commercial insurance were significantly associated with higher odds of CRC screening (p< 0.001). Conversely, patients living in more vulnerable census tracts based on the SVI socioeconomic status and housing/transportation domain had lower odds of having CRC screening (p< 0.001). Finally, there was a significant interaction between trend in CRC screening and race. The CRC screening rate increased between 2016 and 2019 and then decreased for all races, but Asian patients had the most significant decrease in CRC screening between 2020 and 2021 (68.3% versus 60.2%, p< 0.001;Figure 1). CONCLUSION(S): This is the first study to demonstrate that the COVID-19 pandemic led to a population-wide decrease in CRC screening volume that disproportionately affected the Asian population and those of lower socioeconomic status. We are currently evaluating whether this impacted stage migration and mortality. (Figure Presented).

EFFECTIVENESS of COVID-19 VACCINATION among PEOPLE LIVING with HIV during AN OUTBREAK

Background: A large-scale community COVID-19 outbreak occurred between April and August 2021 in Taiwan, where non-pharmaceutical interventions (NPIs) have been strictly implemented and COVID-19 vaccination program was not implemented until 1 March, 2021. Although COVID-19 vaccination is recommended for at-risk populations, the vaccine effectiveness in people living with HIV (PLWH) remains incompletely understood. We evaluated the effectiveness of COVID-19 vaccination among PLWH during a COVID-19 outbreak in Taiwan. Methods: From 1 March to 30 September, 2021, all adult PLWH without previous SARS-CoV-2 infection were included and advised to receive 2 doses of COVID-19 vaccine. The government-funded vaccination campaign provided different types of COVID-19 vaccine, including ChAdOx1 nCoV-19 (AZD1222), BNT162b2 (Pfizer-BioNTech), mRNA-1273 (Moderna), and MVC-COV1901 (Medigen) vaccines. The primary endpoint of this study was the vaccine effectiveness in preventing COVID-19 among PLWH, which was estimated by comparing incidence rates between the unvaccinated, partially vaccinated, and fully vaccinated groups in a dynamic cohort. Results: During the study period, 3131 PLWH were included, with 99.9% on antiretroviral therapy, 99.8% being MSM and median CD4 count of 627 cells/mm3. In the dynamic cohort, 3128 PLWH contributed 516892 person-days of follow-up (PDFU) to the unvaccinated group, 2476 PLWH contributed 139163 PDFU to the partially vaccinated group, and 236 PLWH contributed 12011 PDFU to the fully vaccinated group (Table). During the follow-up, 37 PLWH (1.2%) acquired SARS-CoV-2 infections. The incidence rate of SARS-CoV-2 infection was 6.4 per 100,000 PDFU in the unvaccinated group, which decreased to 2.9 and 0 per 100,000 PDFU in the partially and fully vaccinated groups, respectively. The adjusted incidence rate ratios were 0.47 (95% CI, 0.17-1.32) in the partially vaccinated group and <0.01 in the fully vaccinated group compared with the unvaccinated group, resulting in vaccine effectiveness rates of 53.4% and 99.9% for single-and 2-dose COVID-19 vaccination, respectively. Conclusion: COVID-19 vaccination was clinically effective among PLWH during the outbreak setting where NPIs were strictly implemented.

Healthcare-associated COVID-19 outbreaks: a nationwide population-based cohort study.

BACKGROUND: Healthcare-associated coronavirus disease 2019 (COVID-19) has significant implications for patients, their companions and healthcare workers (HCWs). Controlling transmission in healthcare settings is critical to reduce deaths due to COVID-19. AIM: To describe the epidemiology and characteristics of healthcare-associated COVID-19 outbreaks and outbreak-related cases. METHODS: The investigation data for each healthcare-associated outbreak that occurred between 15th January 2020 and 31st July 2021 in Taiwan were analysed retrospectively. Confirmed outbreak-associated cases were categorized as HCW cases, patient companion cases or patient cases, and the characteristics of the confirmed cases were compared between these categories. FINDINGS: In total, 54 healthcare-associated COVID-19 outbreaks including 512 confirmed cases were reported. The median number of affected cases per outbreak was six [interquartile range (IQR) 2-12], and the median outbreak duration was 12 days (IQR 4.3-17.0). Only 5.7% and 0.2% of all confirmed cases were partially and fully vaccinated, respectively. Most outbreaks (90%, 48/54) occurred in May and June 2021. HCW cases, companion cases and patient cases accounted for 19.5%, 41.2% and 39.3% of the total cases. Patient cases were significantly older (median age 72 years, IQR 61-83) and had higher 30-day all-cause mortality (37.4%) than HCW cases (median age 41 years, IQR 28-58, 0%) and companion cases (median age 52 years; IQR 42-62, 1%). CONCLUSION: Healthcare-associated COVID-19 outbreaks have a critical impact on patients. Nevertheless, two-thirds of cases in the healthcare-associated outbreaks in this study comprised HCWs and companions. In order to effectively mitigate COVID-19 transmission in healthcare settings, multi-pronged infection prevention and control measures should be implemented and tailored for these three groups.

Baseline characteristics associated with clinical improvement and mortality in hospitalized patients with moderate COVID-19

Background: Remdesivir (RDV) has been shown to shorten recovery time and was well tolerated in patients with severe COVID-19. Here we report baseline characteristics associated with clinical improvement at day (d) 14. Methods: We enrolled hospitalized patients with confirmed SARS-CoV-2 infection, oxygen saturation >94% on room air, and radiological evidence of pneumonia. Patients were randomized 1:1:1 to receive 5d or 10d of intravenous RDV once daily plus standard of care (SoC), or SoC only. For this analysis, patients were followed through discharge, d14, or death. Baseline demographic and disease characteristics associated with clinical improvement in oxygen support (≥2-point improvement on a 7-category ordinal scale ranging from discharge to death) were evaluated using multivariable logistic regression methods. Results: 584 patients were randomized and treated (5/10d RDV, n=384;SoC: n=200). 159 (27%) were ≥65y, 227 (39%) female, 328 (61%) white, 102 (19%) Asian, and 99 (19%) Black. 252 participants (43%) were enrolled in Europe, 260 (45%) North America (NA), and 72 (12%) in Asia. Most patients (483 [83%]) were not on supplemental oxygen but required medical care at baseline. In a multivariable model, 5/10d RDV was significantly positively associated with clinical improvement (adjusted odds ratio [OR] 1.69, 95% CI: 1.08, 2.65;p=0.0226). Significant covariables positively associated with clinical improvement included age < 65y (p< 0.0001) and region of treatment (Europe and NA vs Asia, p< 0.0001 each;Table);other examined factors were not significantly associated with clinical improvement, including gender, race, ethnicity, baseline oxygen support, duration of symptoms and hospitalization, obesity, and baseline transaminase levels. Conclusion: In moderate COVID-19 patients, after adjusting for treatment arm, age < 65y and region (NA vs Asia;Europe vs Asia) were associated with higher rates of clinical improvement. These observations recapitulate younger age as positive prognostic factor, and highlight the differences in the impact of the pandemic globally.

Infection prevention and control for coronavirus disease 2019 (COVID-19) in hospital settings

Coronavirus disease 2019 (COVID-19) is public health emergency of international concern. Since December 2019, COVID-19 spread rapidly to 187 countries, leading to more than 10 million cases within 6 months. Currently, the effective antiviral drugs are limited and SARS-CoV-2 vaccine are under developed. Combating such emerging infectious disease, the best and feasible way is to strengthen and Implement specific infection prevention and control practice to control at the source, control along the path, control at the person, engineering and environmental controls. For healthcare facilities every visitor should be screened and triaged. Healthcare personnel working in facilities must properly use personal protective equipment and adheres to hand hygiene. Also, the hospital environment should undergo appropriate cleaning and surface disinfection. For the public, mask-wearing or social distancing is recommended if community spread is a concern. These Infection prevention and control measures are the cornerstones in the context of COVID-19 pandemic. © 2020 Society of Internal Medicine of Taiwan. All rights reserved.